Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

Gaucher Disease, Type 1 Clinical Trial

Official title:

Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Adult Patients With Type 1 Gaucher Disease, Previously on a Stable Dose of VPRIV for at Least 3 Months: an Extension of the Investigator-initiated Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04120506
• Other study ID #: 0075-15-SZMC
• Status: Completed
• Phase: Phase 4
• Start date: January 10, 2016
• Est. completion date: January 1, 2022

Study information

• Verified date: October 2022
• Source: Shaare Zedek Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: In order to allow our satisfied patients, who have successfully completed 24 months of rapid intravenous infusion of Velaglucerase alfa (VPRIV), to continue with the 10 minutes IV therapy, the clinical trial framework must be extended; and this extension is important for the assessment of long term benefit (up to 5 years) of this regimen of administration of Velaglucerase alfa..

Suggested trial: An additional 36 months home therapy follow up of safety and efficacy of rapid intravenous infusion of Velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease.

Patients must have completed the prior 4 parts / 24 months of the protocol before enrolling into this extension phase ("Part 5") and have provided a new consent before entering PART 5 of the study.

Patients must not have experienced clinically significant AEs, including allergic reactions, in any of the prior study parts of this protocol to be eligible to participate, and have maintained stability in the key disease features.

All infusions of 10' will be given in the context of home therapy. "Clinically significant" AEs will be determined by the PI using standard description of AEs as previously described at phase 3, and if necessary will support withdrawal of the patient from the study.

Description:

Every 6 months, patients will be required to come for routine checkups at SZMC, where the following tests will be performed:

• Complete Blood Count (CBC)

• Routine serum biochemistry including liver function tests (LFTs)

• Plasma biomarker lyso Gb-1

• Height & weight & calculation of BMI

• Physical examination and medical history elicited including concomitant medications

• Ultrasound for spleen and liver volumes

In addition, the following tests will be performed at 12, 24 and 36 months:

• Echocardiography

• Electrocardiogram (ECG)

• Urinalysis

• HRQoL questionnaire (TBD)

At each home visit, the following assessments will be performed by the study nurse:

Queries regarding AEs and changes in clinically relevant Gaucher parameters as described by the patient (e.g., bone pain), inter-current illnesses, etc.

Patients will be required to complete the End-of-study visit, including the final infusion at 10', at SZMC. This final visit will include in addition to the usual safety and efficacy assessments and routine tests, (mentioned above) also, DEXA and anti-drug antibodies.

In addition, we would perform a 4th PK measurement at end of the extension period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 1, 2022
• Est. primary completion date: January 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 75 Years

Eligibility

Inclusion Criteria:

• Aged 18-75 years, non-splenectomized Enzymatic diagnosis & molecular analysis indicative of type 1 Gaucher disease Receiving VPRIV for at least 6 infusions (3 months) prior to Baseline at a constant dose and frequency and without clinically significant AEs including allergic reactions

Exclusion Criteria:

• Experience of a clinically significant AE to VPRIV at any time in the past Existence of a clinically significant co-morbidity

Related Conditions & MeSH terms

• Gaucher Disease
• Gaucher Disease, Type 1

Intervention

Drug:
• VPRIV
Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Shaare Zedek Medical Center	Shire

References & Publications (1)

Zimran A, Revel-Vilk S, Becker-Cohen M, Chicco G, Arbel N, Rolfs A, Szer J. Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease. Am J Hematol. 2018 Sep;93(9):E246-E248. doi: 10.1002/ajh.25205. Epub 2018 Aug 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of change from baseline in blood pressure for rapid infusion-1	measured by blood pressure pre and post infusion	9 months
Primary	Incidence of change from baseline in heart rate for rapid infusion-1	measured by heart rate pre and post infusion	9 months
Primary	Incidence of change from baseline in temperature for rapid infusion-1	measured by temperature pre and post infusion	9 months
Secondary	Non deterioration in Gaucher manifestations- stability in platelet counts	Efficacy secondary endpoints are non-deterioration (defined as stability) in platelet count	9 months
Secondary	Non deterioration in Gaucher manifestations- stability in hemaglobin count	Efficacy secondary endpoints are non-deterioration (defined as stability) in hemaglobin count	9 months
Secondary	Non deterioration in Gaucher manifestations- measured by liver volume	Efficacy secondary endpoints are non-deterioration (defined as stability) in organ volumes of liver volume (as previously defined in the TKT034 clinical trial)	9 months
Secondary	Non deterioration in Gaucher manifestations- measured by spleen volumes	Efficacy secondary endpoints are non-deterioration (defined as stability) in organ volumes of spleen volume (as previously defined in the TKT034 clinical trial)	9 months
Secondary	Non deterioration in Gaucher manifestations- measured by lack of elevated biomarker- Lyso-GB1	Efficacy secondary endpoints are non-deterioration (defined as stability) by lack of sustained increases in the biomarkers.	9 months